SK8332002A3 - Novel processes for making- and a new crystalline form of leflunomide - Google Patents
Novel processes for making- and a new crystalline form of leflunomide Download PDFInfo
- Publication number
- SK8332002A3 SK8332002A3 SK833-2002A SK8332002A SK8332002A3 SK 8332002 A3 SK8332002 A3 SK 8332002A3 SK 8332002 A SK8332002 A SK 8332002A SK 8332002 A3 SK8332002 A3 SK 8332002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- leflunomide
- solvent
- form iii
- solution
- crystals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17123799P | 1999-12-16 | 1999-12-16 | |
US17122899P | 1999-12-16 | 1999-12-16 | |
US18264700P | 2000-02-15 | 2000-02-15 | |
US20241600P | 2000-05-08 | 2000-05-08 | |
PCT/US2000/033866 WO2001043742A1 (en) | 1999-12-16 | 2000-12-14 | Novel processes for making- and a new crystalline form of- leflunomide |
Publications (1)
Publication Number | Publication Date |
---|---|
SK8332002A3 true SK8332002A3 (en) | 2003-04-01 |
Family
ID=27496942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK833-2002A SK8332002A3 (en) | 1999-12-16 | 2000-12-14 | Novel processes for making- and a new crystalline form of leflunomide |
Country Status (15)
Country | Link |
---|---|
US (3) | US6610718B2 (pl) |
EP (1) | EP1242077A4 (pl) |
JP (1) | JP2003517011A (pl) |
KR (1) | KR20020067545A (pl) |
CN (1) | CN1411373A (pl) |
AU (1) | AU779931B2 (pl) |
CA (1) | CA2397601A1 (pl) |
CZ (1) | CZ20022000A3 (pl) |
HR (2) | HRP20020521A2 (pl) |
HU (1) | HUP0204069A3 (pl) |
IL (1) | IL149792A0 (pl) |
PL (1) | PL356243A1 (pl) |
SK (1) | SK8332002A3 (pl) |
WO (1) | WO2001043742A1 (pl) |
YU (1) | YU45102A (pl) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE207065T1 (de) * | 1997-08-08 | 2001-11-15 | Aventis Pharma Gmbh | Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid |
CN1411373A (zh) * | 1999-12-16 | 2003-04-16 | 特瓦制药工业有限公司 | 制备来氟米特的新方法和新晶形的来氟米特 |
US20030153585A1 (en) * | 2000-01-13 | 2003-08-14 | Sven-Alexander Schreder | Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
ATE292966T1 (de) * | 2000-02-15 | 2005-04-15 | Teva Pharma | Methode zur synthetisierung von leflunomid |
US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
WO2006103506A1 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Sertraline-containing pharmaceutical compositions and a process for preparation thereof |
WO2008040149A1 (en) * | 2006-09-05 | 2008-04-10 | Dexian Dou | Composition and method for treating immune-mediated skin disorders |
CN101143834B (zh) * | 2006-09-15 | 2010-09-08 | 欣凯医药化工中间体(上海)有限公司 | N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法 |
WO2009004374A1 (en) | 2007-06-29 | 2009-01-08 | Generics [Uk] Limited | Process for introduction of hydroxyethoxy side chain in bosentan |
NZ600010A (en) | 2007-10-24 | 2013-11-29 | Generics Uk Ltd | Novel crystalline forms of bosentan, processes for their preparation and uses thereof |
US8785461B2 (en) | 2008-02-08 | 2014-07-22 | Generics [Uk] Limited | Process for preparing bosentan |
EP2350028A1 (en) | 2008-11-03 | 2011-08-03 | Generics [UK] Limited | Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers |
CN101817797B (zh) * | 2009-02-26 | 2013-04-10 | 江苏亚邦爱普森药业有限公司 | 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法 |
MX2021001169A (es) | 2013-11-15 | 2023-02-10 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. |
US11801232B2 (en) * | 2019-11-27 | 2023-10-31 | Yale University | Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway |
CN112898215B (zh) * | 2021-02-04 | 2022-11-08 | 美罗药业股份有限公司 | 一种来氟米特晶型i的制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
US5268382A (en) * | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
DE3534440A1 (de) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
GB8619432D0 (en) * | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
DK0527736T3 (da) * | 1990-05-18 | 1997-10-20 | Hoechst Ag | Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler. |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
DE19610955A1 (de) * | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
DE19711800A1 (de) * | 1997-03-21 | 1998-09-24 | Hoechst Ag | Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung |
ATE207065T1 (de) | 1997-08-08 | 2001-11-15 | Aventis Pharma Gmbh | Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid |
EP0933633A1 (en) * | 1997-12-11 | 1999-08-04 | Hoechst Marion Roussel Deutschland GmbH | Process for obtaining L-dihydroorotic acid and use thereof |
US7691890B2 (en) * | 1998-03-11 | 2010-04-06 | James W. Williams | Anti-viral uses of leflunomide products |
US6303652B1 (en) * | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE19908527C2 (de) * | 1999-02-26 | 2001-08-30 | Aventis Pharma Gmbh | Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid |
ATE248835T1 (de) * | 1999-06-25 | 2003-09-15 | Vertex Pharma | Prodrugs von impdh-inhibierenden carbamaten |
CN1411373A (zh) * | 1999-12-16 | 2003-04-16 | 特瓦制药工业有限公司 | 制备来氟米特的新方法和新晶形的来氟米特 |
ATE292966T1 (de) * | 2000-02-15 | 2005-04-15 | Teva Pharma | Methode zur synthetisierung von leflunomid |
US6548527B2 (en) * | 2000-03-27 | 2003-04-15 | The General Hospital Corporation | Treatments for immune-mediated ear disorders |
WO2002013822A1 (en) * | 2000-08-14 | 2002-02-21 | Teva Pharmaceutical Industries Ltd. | Micronized leflunomide |
EA014224B1 (ru) * | 2000-08-24 | 2010-10-29 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Селективные модуляторы андрогенового рецептора и способы их применения |
JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
US20040229849A1 (en) * | 2002-09-24 | 2004-11-18 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
US20050064038A1 (en) * | 2003-08-13 | 2005-03-24 | Dinh Thomas Q. | Active agent delivery systems including a single layer of a miscible polymer blend, medical devices, and methods |
EP1684820A2 (en) * | 2003-08-13 | 2006-08-02 | Medtronic, Inc. | Active agent delivery systems including a miscible polymer blend, medical devices, and methods |
US20050053600A1 (en) * | 2003-09-09 | 2005-03-10 | Lane Thomas E. | Methods for treating rheumatoid arthritis |
-
2000
- 2000-12-14 CN CN00817283A patent/CN1411373A/zh active Pending
- 2000-12-14 CA CA002397601A patent/CA2397601A1/en not_active Abandoned
- 2000-12-14 KR KR1020027007575A patent/KR20020067545A/ko not_active Application Discontinuation
- 2000-12-14 YU YU45102A patent/YU45102A/sh unknown
- 2000-12-14 CZ CZ20022000A patent/CZ20022000A3/cs unknown
- 2000-12-14 SK SK833-2002A patent/SK8332002A3/sk unknown
- 2000-12-14 HU HU0204069A patent/HUP0204069A3/hu unknown
- 2000-12-14 US US09/736,727 patent/US6610718B2/en not_active Expired - Fee Related
- 2000-12-14 PL PL00356243A patent/PL356243A1/pl not_active Application Discontinuation
- 2000-12-14 IL IL14979200A patent/IL149792A0/xx unknown
- 2000-12-14 WO PCT/US2000/033866 patent/WO2001043742A1/en not_active Application Discontinuation
- 2000-12-14 JP JP2001544880A patent/JP2003517011A/ja active Pending
- 2000-12-14 AU AU25788/01A patent/AU779931B2/en not_active Ceased
- 2000-12-14 EP EP00989253A patent/EP1242077A4/en not_active Withdrawn
-
2002
- 2002-06-14 HR HR20020521A patent/HRP20020521A2/hr not_active Application Discontinuation
-
2003
- 2003-04-08 US US10/410,493 patent/US6806373B2/en not_active Expired - Fee Related
-
2004
- 2004-07-22 US US10/897,778 patent/US20050004191A1/en not_active Abandoned
-
2005
- 2005-02-23 HR HR20050176A patent/HRP20050176A2/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ20022000A3 (cs) | 2003-02-12 |
EP1242077A4 (en) | 2006-01-04 |
HUP0204069A2 (hu) | 2003-04-28 |
US20050004191A1 (en) | 2005-01-06 |
WO2001043742A1 (en) | 2001-06-21 |
PL356243A1 (pl) | 2004-06-28 |
AU779931B2 (en) | 2005-02-17 |
HRP20020521A2 (en) | 2004-08-31 |
US20010031878A1 (en) | 2001-10-18 |
HUP0204069A3 (en) | 2005-01-28 |
US20030203952A1 (en) | 2003-10-30 |
US6610718B2 (en) | 2003-08-26 |
KR20020067545A (ko) | 2002-08-22 |
CN1411373A (zh) | 2003-04-16 |
IL149792A0 (en) | 2002-11-10 |
HRP20050176A2 (en) | 2005-08-31 |
YU45102A (sh) | 2006-01-16 |
JP2003517011A (ja) | 2003-05-20 |
AU2578801A (en) | 2001-06-25 |
EP1242077A1 (en) | 2002-09-25 |
US6806373B2 (en) | 2004-10-19 |
CA2397601A1 (en) | 2001-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002366383B2 (en) | Polymorphs of clopidogrel hydrogensulfate | |
CA2651353C (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form .alpha. | |
SK8332002A3 (en) | Novel processes for making- and a new crystalline form of leflunomide | |
KR20030017569A (ko) | 카르베딜올 | |
US6767913B2 (en) | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms | |
US7977348B2 (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α | |
WO2021019448A1 (en) | Process for the preparation of transthyretin dissociation inhibitor | |
US8134032B2 (en) | Crystalline modifications of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
JP2019523273A (ja) | ベリノスタットの多形形態、およびその調製のためのプロセス | |
TW201736343A (zh) | 1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺鹽之新穎晶形 | |
EP1257270B1 (en) | A method for synthesizing leflunomide | |
US20080090833A1 (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha | |
CA2437402A1 (en) | New crystal forms of oxcarbazepine and processes for their preparation | |
WO2012090221A1 (en) | Novel salts of imatinib | |
CN111732586B (zh) | 含炔基化合物盐的晶型、制备方法及应用 | |
KR100869017B1 (ko) | 페닐에탄올아민의 결정질 형태, 이의 제조 방법 및 이를포함하는 제약 조성물 | |
KR20090014225A (ko) | (r)-5-(2-아미노에틸)-1-(6,8-디플루오로크로만-3-일)-1,3-디히드로이미다졸-티온 히드로클로라이드의 다형체 | |
EP2072510A1 (en) | Crystalline form of azelastine | |
AU2005202109A1 (en) | Novel processes for making- and a new crystalline form of- leflunomide | |
WO2018042320A1 (en) | Salts of betrixaban and processes for preparation thereof | |
EP4355737A1 (en) | Polymorphs of 2-(3,5-dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid | |
WO2010010058A1 (en) | Method of preparing anhydrous alfusozin hydrochloride | |
WO2014009969A2 (en) | Novel polymorphs of azilsartan |